Secukinumab: Phase IIIb data

The 52-week, double-blind, international Phase IIIb CLEAR trial in 679 patients with moderate to severe plaque psoriasis

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE